# Mutant KRAS Heterogeneity Shapes Nuclear Architecture During Pancreatic Cancer Initiation

**Authors:** Gareth Pollin, Angela J. Mathison, Elise N. Leverence, Thiago Milech De Assuncao, Juan Iovanna, Johnny C. Hong, Michael T. Zimmermann, Raul Urrutia, Gwen Lomberk

PMC · DOI: 10.3390/epigenomes10010019 · 2026-03-10

## TL;DR

Different KRAS mutations in pancreatic cancer lead to distinct nuclear changes, affecting how the disease starts.

## Contribution

This study reveals how specific KRAS mutations drive unique nuclear architectural changes during early pancreatic cancer initiation.

## Key findings

- KRAS G12D induces significant nuclear remodeling compared to G12R.
- G12D leads to changes in nuclear size, shape, and sub-compartments like the nucleolus.
- Mutation-specific KRAS signaling rapidly alters epigenetic states in early PDAC.

## Abstract

Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) arises predominantly from activating KRAS mutations, yet individual genetic variants differ markedly in signaling output and clinical impact. G12D, the most prevalent variant, strongly drives oncogenic programs, whereas G12R signals less efficiently through the AKT and ERK pathways and is associated with longer patient survival than G12D-driven PDAC. Methods: To elucidate how these differences influence early cellular transformation, we expressed a panel of KRAS mutants in non-cancerous pancreatic ductal epithelial cells as a model of early PDAC initiation and profiled transcriptional and phospho-proteomic responses. We next examined whether epigenetic differences translate into mutation-specific changes in nuclear organization using quantitative imaging of G12D- and G12R-expressing nuclei at 24 and 48 h. Results: Each variant established a unique regulatory program enriched for chromatin remodelers, histone modifiers, and nuclear structural factors, indicating that variant-specific KRAS signaling rapidly develops divergent epigenetic states. Integrated transcriptomic and phospho-proteomic analyses identified G12D and G12R as the most divergent variants. G12D induced pronounced nuclear remodeling, including increased nuclear size, irregular morphology, and reorganization of the nucleolus and spliceosome, consistent with extensive chromatin and transcriptional reprogramming. In contrast, G12R elicited a weaker response, with minimal or delayed structural changes. Conclusions: Together, these findings demonstrate that KRAS mutational context in pancreatic ductal epithelial cells shapes early transcriptional reprogramming that actively remodels nuclear architecture and nuclear sub-compartments. This work establishes nuclear structural remodeling as a structural state of KRAS-driven epigenetic dysregulation during PDAC initiation.

## Linked entities

- **Genes:** KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845]
- **Diseases:** pancreatic ductal adenocarcinoma (MONDO:0005184)

## Full-text entities

- **Genes:** DDX5 (DEAD-box helicase 5) [NCBI Gene 1655] {aka G17P1, HLR1, HUMP68, p68}, ATR (ATR checkpoint kinase) [NCBI Gene 545] {aka FCTCS, FRP1, MEC1, SCKL, SCKL1}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, SRSF2 (serine and arginine rich splicing factor 2) [NCBI Gene 6427] {aka PR264, SC-35, SC35, SFRS2, SFRS2A, SRp30b}, EHMT1 (euchromatic histone lysine methyltransferase 1) [NCBI Gene 79813] {aka EHMT1-IT1, EUHMTASE1, Eu-HMTase1, FP13812, GLP, GLP1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, WIZ (WIZ zinc finger) [NCBI Gene 58525] {aka ZNF803}, HDAC5 (histone deacetylase 5) [NCBI Gene 10014] {aka HD5, NY-CO-9}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, ABTB1 (ankyrin repeat and BTB domain containing 1) [NCBI Gene 80325] {aka BPOZ, BPOZ-2, BTB3, BTBD21, EF1ABP, PP2259}, FBL (fibrillarin rRNA 2'-O-methyltransferase) [NCBI Gene 2091] {aka FIB, FLRN, Nop1, RNU3IP1}, Nras (Nras proto-oncogene, GTPase) [NCBI Gene 18176] {aka N-ras}, EHMT2 (euchromatic histone lysine methyltransferase 2) [NCBI Gene 10919] {aka BAT8, C6orf30, G9A, GAT8, KMT1C, NG36}, EMD (emerin) [NCBI Gene 2010] {aka CMD3C, EDMD, LEMD5, STA}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, HDAC1 (histone deacetylase 1) [NCBI Gene 3065] {aka GON-10, HD1, KDAC1, RPD3, RPD3L1}, SOX9 (SRY-box transcription factor 9) [NCBI Gene 6662] {aka CMD1, CMPD1, ENH13, SRA1, SRXX2, SRXY10}, SATB1 (SATB homeobox 1) [NCBI Gene 6304] {aka DEFDA, DHDBV, KTZSL}, PRDM9 (PR/SET domain 9) [NCBI Gene 56979] {aka KMT8B, MEISETZ, MSBP3, PFM6, ZNF899}, ATM (ATM serine/threonine kinase) [NCBI Gene 472] {aka AT1, ATA, ATC, ATD, ATDC, ATE}, NOS1AP (nitric oxide synthase 1 adaptor protein) [NCBI Gene 9722] {aka 6330408P19Rik, CAPON, NPHS22}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, HDAC2 (histone deacetylase 2) [NCBI Gene 3066] {aka HD2, KDAC2, RPD3, YAF1}, Hras (Hras proto-oncogene, GTPase) [NCBI Gene 15461] {aka H-ras, Ha-ras, Harvey-ras, Hras-1, Hras1, Kras2}, HDAC6 (histone deacetylase 6) [NCBI Gene 10013] {aka CPBHM, HD6, JM21, KDAC6, PPP1R90}, CTCF (CCCTC-binding factor) [NCBI Gene 10664] {aka CFAP108, FAP108, MRD21}, Kras (Kras proto-oncogene, GTPase) [NCBI Gene 16653] {aka K-Ras, K-Ras 2, K-ras, Ki-ras, Kras-2, Kras2}, SMAD3 (SMAD family member 3) [NCBI Gene 4088] {aka HSPC193, HsT17436, JV15-2, LDS1C, LDS3, MADH3}, RGPD2 (RANBP2 like and GRIP domain containing 2) [NCBI Gene 729857] {aka NUP358, RANBP2L2, RGP2, ranBP2-like 2}, NUCLEOLIN (nucleolin multifunctional protein) [NCBI Gene 4691] {aka C23, NCL, Nsr1}
- **Diseases:** Pancreatic Cancer (MESH:D010190), pancreatic tumorigenesis (MESH:D010195), lung cancer (MESH:D008175), PDAC (MESH:D021441), injury (MESH:D014947), preneoplastic (MESH:D011230), inflammatory (MESH:D007249), WT (MESH:D009396), cancer (MESH:D009369)
- **Chemicals:** Alexa Fluor 555 (MESH:C000608607), DAPI (MESH:C007293), paraformaldehyde (MESH:C003043), Triton X-100 (MESH:D017830), L-glutamine (MESH:D005973), Alexa Fluor Plus 488 (-), puromycin (MESH:D011691), D-glucose (MESH:D005947), sodium bicarbonate (MESH:D017693), PBS (MESH:D007854), Blasticidin (MESH:C004500), doxy (MESH:D004318)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Human papillomavirus 16 (serotype) [taxon 333760]
- **Mutations:** G12V, Q61R, Q61, Q61H, S17N, G13D, Q61K, G12R
- **Cell lines:** HPNE — Homo sapiens (Human), Telomerase immortalized cell line (CVCL_C466), hTERT-HPNE E6/E7 — Homo sapiens (Human), Transformed cell line (CVCL_C467), CRL-4036 — Sigmodon hispidus (Hispid cotton rat), Spontaneously immortalized cell line (CVCL_YD58), hTERT — Homo sapiens (Human), Transformed cell line (CVCL_E232)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025234/full.md

---
Source: https://tomesphere.com/paper/PMC13025234